Change in the number of shares and votes in Sinch AB (publ)
Stockholm, Sweden – November 30, 2021 – Sinch AB (publ), a global leader in cloud communications for mobile customer engagement, today announced that the number of shares and votes in Sinch AB (publ), registration number 556882-8908 (“Sinch”), amounts to 747,480,901 on November 30, 2021.
The change in the number of shares and votes in November is a result of the issue of totally 1,317,537 new shares in connection with the closing of the acquisitions of MessageMedia and MessengerPeople, as previously communicated.
For further information, please contact
Investor Relations Director
Mobile: +46 721 43 34 59
Chief Strategy Officer & Head of Investor Relations
Mobile: +46 722 45 50 55
Sinch brings businesses and people closer with tools enabling personal engagement. Its leading cloud communications platform lets businesses reach every mobile phone on the planet, in seconds or less, through mobile messaging, voice and video. Sinch is a trusted software provider to mobile operators, and its platform powers business-critical communications for many of the world’s largest companies. Sinch has been profitable and fast-growing since its foundation in 2008. It is headquartered in Stockholm, Sweden, and has local presence in more than 40 countries. Shares are traded at NASDAQ Stockholm: XSTO:SINCH. Visit us at sinch.com.
This information is information that Sinch AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act (1991:980). The information was submitted for publication, through the agency of the contact person set out above, at 17:35 CEST on November 30, 2021.
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Verisk Welcomes Olumide Soroye to Its Board of Directors18.8.2022 22:15:00 CEST | Press release
JERSEY CITY, N.J., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Verisk (Nasdaq: VRSK) today announced that Olumide Soroye has been appointed independent director of the company’s Board of Directors effective immediately. Soroye brings three decades of leadership experience across multiple industries. “Olumide’s experience in software, data analytics, AI, and growth-minded leadership make him an exceptional addition to Verisk’s board,” Verisk CEO Lee Shavel said. “We look forward to working closely with Olumide to ensure that we continue to drive value and positive impact for all Verisk stakeholders including shareholders, clients, employees and partners.” Soroye, 50, is president and chief executive officer of Fortive Corporation’s Intelligent Operating Solutions segment. Before Fortive, he held leadership roles at CoreLogic, where he was managing director of property intelligence & risk management, and QuinStreet, where he was senior vice president of the company’s technology and home services b
Galapagos receives transparency notification from FMR LLC18.8.2022 22:01:00 CEST | Press release
Mechelen, Belgium;18 August 2022, 22.01CET;regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from FMR LLC. Pursuant to Belgian transparency legislation1, Galapagos received a transparency notification on 15 August 2022 from FMR LLC, who notified that it holds 3,740,842 of Galapagos’ voting rights, consisting of 3,740,842 ordinary shares. FMR LLC controls investment funds FIAM Holdings LLC, Fidelity Management & Research Company LLC, Fidelity Management Trust Company and Strategic Advisers LLC, of which Fidelity Management & Research Company LLC increased its position to 3,303,128 voting rights, and no longer holds any equivalent financial instruments, and Strategic Advisers LLC decreased its position to 10,082 voting rights. FMR LLC's holding of 3,740,842 Galapagos' voting rights represents 5.69% of Galapagos' currently outstanding 65,728,511 shares. FMR LLC thus remains above the 5% threshold of Galapagos’ voting rights considering the
Bavarian Nordic Expands Capacity with U.S. Contract Manufacturer for Filling of Smallpox/Monkeypox Vaccines18.8.2022 20:24:11 CEST | Press release
U.S. FDA approved facility operated by Grand River Aseptic Manufacturing will assist in filling of already manufactured bulk vaccine to expedite deliveries of monkeypox vaccines to the U.S.Agreement will significantly expand Bavarian Nordic’s manufacturing capacity for the benefit of the U.S. and globallyExpedited tech transfer has already started, allowing for manufacturing of first doses in 2022 COPENHAGEN, Denmark, August 18, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Company has entered into an agreement with Grand River Aseptic Manufacturing (GRAM), a U.S. based contract manufacturer, for fill and finish of JYNNEOS smallpox/monkeypox vaccine. As announced on July 15, 2022, Bavarian Nordic received an additional order for 2.5 million doses the vaccine from the U.S. Biomedical Advanced Research and Development Authority (BARDA), a part of the Administration for Strategic Preparedness and Response (ASPR), which will be filled at GRAM using bulk vaccine already ma
Bavarian Nordic udvider produktionskapaciteten via aftale med amerikansk kontraktproducent om fyldning af koppe-/abekoppevacciner18.8.2022 20:24:11 CEST | pressemeddelelse
Den FDA-godkendte kontraktproducent, Grand River Aseptic Manufacturing, vil bistå med fyldning af allerede produceret råvaccine med henblik på at fremskynde leverancer af abekoppevacciner til USAAftalen vil øge Bavarian Nordics produktionskapacitet markant til gavn for både USA og lamde globaltEn accelereret procesoverførsel er allerede startet, hvilket muliggør produktion af de første doser i 2022 KØBENHAVN, Danmark, 18. august 2022 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at selskabet har indgået en aftale med den amerikanske kontraktproducent Grand River Aseptic Manufacturing (GRAM) om fyldning af JYNNEOS koppe-/abekoppevaccine. Som meddelt den 15. juli 2022, modtog Bavarian Nordic en yderligere ordre på 2,5 mio. doser af vaccinen fra U.S. Biomedical Advanced Research and Development Authority (BARDA), en del af Administration for Strategic Preparedness and Response (ASPR), som vil blive påfyldt på GRAMs facilitet ved brug af den råvaccine, der allerede er fremstillet og fa
PCI Biotech: Company update18.8.2022 18:05:06 CEST | Press release
Oslo (Norway), 18 August 2022 – PCI Biotech (OSE: PCIB), a cancer-focused biopharma company developing innovative therapeutics that address significant unmet medical needs, today announced that the previously reported efforts to finance a planned Ph II trial in head and neck cancer have not under the current market conditions resulted in a feasible way forward. As PCI Biotech will not conduct a company-sponsored Ph II trial with the fimaVacc technology a reduction of the clinical team will be enacted during the second half of 2022. Further details about the development plans for the non-clinical assets will be given at the upcoming Q2 reporting, scheduled 31st August 2022. The cash position per Q2 2022 is around NOK 76 million and the financial runway is estimated to be towards the end of 2023. Contact information: Ronny Skuggedal, Interim CEO firstname.lastname@example.org Mobile: +47 9400 5757 About PCI Biotech PCI Biotech is a biopharmaceutical company focusing on development and commercialisatio